HLS Therapeutics Inc (TSE:HLS) has released an update.
HLS Therapeutics Inc. has reported a mixed second quarter for 2024 with revenues of $14.5 million, marking a slight decrease from the previous year, but showcased a strong 9% growth in revenue excluding royalty portfolio and an 86% increase in Adjusted EBITDA when the same exclusion applies. The pharmaceutical company also highlighted the successful sale of the Xenpozyme royalty asset for up to $45.75 million and the signing of a Product Listing Agreement for Vascepa in Alberta, indicating a strategic bolstering of their financial position and a focus on core products like Clozaril and Vascepa.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
